

# Life Science Leader

Connect. Collaborate. Contribute.

JULY 2014



# DEVELOPMENT & MANUFACTURING OUTSOURCING INSIGHTS

## The Latest Industry Trends And Proprietary Data From Nice Insight Survey Results

# YOUR SUCCESSFUL OUTSOURCING STRATEGY BEGINS **HERE**



WHEN IT COMES TO DEVELOPMENT AND MANUFACTURING,  
YOUR OUTSOURCING STRATEGY CAN MAKE OR BREAK YOU.  
LEARN WHAT SUCCESS LOOKS LIKE FROM THE EXPERTS.

---

## **Outsourced**Pharma**WEST**

CONFERENCE AND EXHIBITION

**HYATT REGENCY | SAN FRANCISCO**

**NOVEMBER 10 & 11, 2014**

814.897.7700

INFO@OUTSOURCEDPHARMAWEST.COM

OUTSOURCEDPHARMAWEST.COM  
FOR CONFERENCE AGENDA  
& REGISTRATION



# High-Quality Used Pharmaceutical-Processing Equipment!

877.503.8635 or [pharmaceutical@fedequip.com](mailto:pharmaceutical@fedequip.com)



The Equipment Solutions Company  
[www.fedequip.com](http://www.fedequip.com)

Federal Equipment Company offers high-quality pharmaceutical processing and packaging equipment at a fraction of the price and lead-time required for new equipment. We also provide investment recovery services for single items, complete processing lines, or entire manufacturing facilities, including rigging, dismantling, transportation, storage.

**Visit Us Today!**

- Capsule Fillers
- Centrifuges
- Coating Pans
- Tablet Presses
- Dryers
- Fluid Bed Dryers
- Fluid Bed Granulators
- High Shear Mixers
- Mixers
- Lab Equipment
- Tanks
- Filters
- Roller Compactors
- Blister Lines
- Bottling Lines



SOLID DOSE EXPERTS  
  
**TECHCEUTICALS**

Techceuticals, the leader in solid dosage training, welcomes companies to take advantage of their Pilot Manufacturing Lab equipped with moisture and particle analyzers, blenders, mills, wet and dry granulating, tablet presses, coating, and encapsulation. Techceuticals assists customers with equipment selection, formula development, optimization, and training. Visit [www.techceuticals.com](http://www.techceuticals.com)

**Your source for  
surplus Pfizer  
equipment!**



**p. 216.271.3500 f. 216.271.5210**  
[pharmaceutical@fedequip.com](mailto:pharmaceutical@fedequip.com)  
[www.fedequip.com](http://www.fedequip.com)  
8200 Bessemer Avenue  
Cleveland, Ohio, USA 44127



**p. 216.658.8038**  
**f. 216.916.4383**

[sales@techceuticals.com](mailto:sales@techceuticals.com)  
[www.techceuticals.com](http://www.techceuticals.com)  
2917 E. 79th Street  
Cleveland, Ohio 44104

# Welcome to Life Science Leader


JULY 2014 CMO SUPPLEMENT VOL. 6 NO. 7

[@RFWrightLSL](#)
[linkedin.com/in/robertfwright](#)
[pinterest.com/rfwrightsl](#)
[facebook.com/LifeScienceLeader](#)

WWW.LIFESCIENCELEADER.COM

## EDITOR'S NOTE

*Don't Let Big Data Analytics Prevent You From Being Brilliant At The Basics*



**LIFE SCIENCE LEADER** (ISSN: 21610800) Vol. 6, No. 7 is published monthly by Jameson Publishing, Inc. at Knowledge Park, 5340 Fryling Road, Suite 300, Erie, PA 16510-4672. Phone (814) 897-9000, Fax (814) 899-5580. Periodical postage paid at Erie, PA 16510 and additional mailing offices. Copyright 2014 by Peterson Partnership. All rights reserved. Printed in the USA.

**SUBSCRIPTION RATES** for qualified readers in the U.S. \$0. For nonqualified readers in the U.S. and all other countries \$97 for one year. If your mailing address is outside the U.S. or Canada, you can receive the magazine digitally if you provide a valid email address.

**POSTMASTER:** Send address corrections (Form 3579) to Life Science Leader, Knowledge Park, 5340 Fryling Road, Suite 300, Erie, PA 16510-4672. **PUBLICATIONS AGREEMENT** No. 40722524 c/o AIM, 7289 Torbram Road, Mississauga, ON L4T 1G8

RESEARCH CONDUCTED BY:

**niceinsight**

Marketing Intelligence by That's Nice

WWW.NICEINSIGHT.COM



**Delivering Your Product  
in a Single Unit Dose**

# Unither

US plant dedicated to fill and finish  
of solid dose, hardshell capsules and  
liquid dosage forms.

Legacy of over 50 years of commercial  
pharmaceutical production with  
specialties in sustained release and  
controlled substance formulations.

**Unither's first North American  
liquid stick pack line launching in  
summer 2014.**

**Unither Manufacturing LLC**  
755 Jefferson Road  
Rochester, NY 14623

**US Inquiries:**  
+1 585 475 9000  
[inquiries@unither-pharma.com](mailto:inquiries@unither-pharma.com)  
[www.unither-pharma.com](http://www.unither-pharma.com)



# Don't Let Big Data Analytics Prevent You From Being Brilliant At The Basics




**ROB WRIGHT** Chief Editor



When I think of the potential Big Data presents for the field of life sciences, it reminds me of *The Rime of the Ancient Mariner* — “Water, water, everywhere, nor any drop to drink.” Like the salt water ocean surrounding a thirsty sailor adrift, we are seemingly surrounded by Big Data yet struggle to tap its potential. Worse yet, from my perspective, most of those in our industry are only viewing the tip of the iceberg when it comes to looking at how to use Big Data — ignoring the massive amounts residing below the water's surface. The McKinsey Global Institute estimates the application of Big Data strategies *could* generate up to \$100 billion in value annually across the U.S. healthcare system by optimizing innovation, improving the efficiency of R&D and clinical trials, and providing new tools for physicians, consumers, insurers, and regulators. Like a majority of the research and discussions surrounding the application of Big Data in the pharmaceutical and biopharmaceutical industries, the focus seems to be on that which garners the most attention (e.g., skyrocketing drug discovery and development costs or rising healthcare costs). It seems little attention is paid to the potential value that could be created in the U.S. healthcare system by being brilliant at the basics, such as manufacturing or shipping. Who cares how stylish a car is if it doesn't start?

A December 2013 *Harvard Business Review* article noted that most companies investing in data scientists, data warehouses, and data analytics software have little to show for their efforts. Why? Most companies don't do a

good job of managing Big Data. Further, they don't know how to analyze it in ways that enhance understanding and then make changes in response to new insights. Jeanne Ross (MIT Sloan Center For Information Systems Research), Cynthia Beath (University of Texas at Austin), and Anne Quaadgras (MIT Sloan Center for Information Systems Research) say that until a company learns how to use data and analysis to support its *operating decisions*, it will not be in a position to benefit from Big Data. In other words, what is your core business and how can you apply Big Data to make evidenced-based decisions? UPS is an interesting example. The shipping company tracks data on more than 16 million packages per day for nearly 9 million customers from telematics sensors in over 46,000 vehicles. Why? To be able to determine trends (drop-offs and pickups) in real time and reconfigure the most efficient route of navigation. What kind of impact can this have? In 2011 UPS reported saving more than 8.4 million gallons of fuel by cutting 85 million miles off of daily routes. Not only does this improved efficiency make UPS “greener” and more sustainable, but it also translates into significant savings. UPS estimates saving just one daily mile driven per driver saves the company \$30 million.

In order to help you improve your efficiencies in selecting a strategic partner for your drug development and manufacturing needs, we decided to put together some Big Data trends of our own via this special supplement. However, please don't let this data-driven research and analysis by Nice Insight prevent you from being brilliant at the basics. For example, when you are on a site tour, don't let a presentation on how a CMO is using Big Data analytics to improve manufacturing efficiencies prevent you from asking — “So, when was the roof last replaced/inspected?” Big Data, without application of intellect, doesn't make a good business decision model. 

## Life Science Leader

JULY 2014 VOL. 6 NO. 7

**LIFE SCIENCE LEADER**  
5340 Fryling Rd.  
Suite 300  
Erie, PA 16510-4672

Telephone: 814 897 7700  
Fax: 814 899 4648

[WWW.LIFESCIENCELEADER.COM](http://WWW.LIFESCIENCELEADER.COM)

### VP OF PUBLISHING

Jon Howland  
814 897 9000 / Ext. 203  
[jon.howland@lifescienceleader.com](mailto:jon.howland@lifescienceleader.com)

### CHIEF EDITOR

Rob Wright  
814 897 9000 / Ext. 140  
[rob.wright@lifescienceleader.com](mailto:rob.wright@lifescienceleader.com)

### EXECUTIVE EDITOR

Wayne Koberstein  
[wayne.koberstein@lifescienceleader.com](mailto:wayne.koberstein@lifescienceleader.com)

### EDITORIAL DIRECTOR

Dan Schell  
814 897 9000 / Ext. 284  
[dan.schell@lifescienceleader.com](mailto:dan.schell@lifescienceleader.com)

### ASSOC. PUBLISHER/BIOPHARM & LAB

Shannon Primavere  
814 897 7700 / Ext. 279  
[shannon.primavere@lifescienceleader.com](mailto:shannon.primavere@lifescienceleader.com)

### PUBLISHER/OUTSOURCING

Cory Coleman  
814 897 7700 / Ext. 108  
[cory.coleman@lifescienceleader.com](mailto:cory.coleman@lifescienceleader.com)

### GROUP PUBLISHER/OUTSOURCING

Ray Sherman  
814 897 7700 / Ext. 335  
[ray.sherman@lifescienceleader.com](mailto:ray.sherman@lifescienceleader.com)

### BUSINESS DEVELOPMENT MANAGER

Mike Barbalaci  
814 897 7700 / Ext. 218  
[mike.barbalaci@lifescienceleader.com](mailto:mike.barbalaci@lifescienceleader.com)

### SR. ACCOUNT EXECUTIVE

Scott Moren  
814 897 7700 / Ext. 118  
[scott.moren@lifescienceleader.com](mailto:scott.moren@lifescienceleader.com)

### PUBLISHER, CLINICAL & CONTRACT RESEARCH

Sean Hoffman  
724 940 7557 / Ext. 165  
[sean.hoffman@lifescienceleader.com](mailto:sean.hoffman@lifescienceleader.com)

### PRODUCTION DIRECTOR

Lynn Netkowicz  
814 897 9000 / Ext. 205  
[lynn.netkowicz@jamesonpublishing.com](mailto:lynn.netkowicz@jamesonpublishing.com)

### DIRECTOR OF AUDIENCE DEVELOPMENT

Mindy Fadden  
814 897 9000 / Ext. 208  
[mindy.fadden@jamesonpublishing.com](mailto:mindy.fadden@jamesonpublishing.com)

### ACCOUNT EXECUTIVE, PACKAGING & SERIALIZATION

Evan Lagace  
814 897 7700 / Ext. 119  
[evan.lagace@lifescienceleader.com](mailto:evan.lagace@lifescienceleader.com)

Empowered  
To Deliver.



**Charles Brown**  
*Key Account Representative*



Product Quality.

Service Excellence.

**Robert Rael**  
*Quality Assurance  
Technical Evaluator*



Client Satisfaction.

**Kristin Calloway**  
*Contracts Manager*



**OSO BIO**<sup>®</sup>  
The injectables cmo

There's never been a more challenging time for the sterile injectables industry. Compliance can be tricky. Cost-efficiency is critical. And quality isn't just a box to tick off, it must be hardwired into every step of the process.

At OSO BioPharmaceuticals, we've established some of the most rigorous and measurable quality guidelines in the business. And we've empowered our people to meet and surpass those guidelines, whatever it takes. Of course, that empowerment isn't just granted...it's earned.

OsoBio. Learn how we can be empowered to deliver for you.

*osobio.com / Albuquerque, New Mexico / Phone: 505-923-1500*



# ONCOLOGY TRENDS IN 2014

The latest industry trends and proprietary data from Nice Insight survey results




Outsourcing has proven to be valuable to biopharmaceutical companies of all sizes. And different types of drug makers, from virtual biotechs to Big Pharma, have implemented outsourcing programs for a variety of reasons. There are commonalities in both outsourcing motivations and practices across the various buyer groups, as well as differences. Knowing which services are outsourced by your peers, as well as which factors are most relevant to their outsourcing strategy, may add value to your organization's 2014 planning and future outsourcing initiatives.

# RESPONDENT PROFILE INFORMATION

Research conducted by Nice Insight [n=886]


## BY COMPANY TYPE

■ Biotech ■ Emerging Biotech ■ Specialty Pharma ■ Big Pharma ■ Emerging Pharma






## BY ANNUAL OUTSOURCING EXPENDITURE

■ Less than 10M USD per year ■ 10 to 50M USD per year ■ 50M+ USD per year



## BY REGION



**3.5** DIFFERENT  
THERAPEUTIC AREAS

Oncology drug developers will average 3.5 different therapeutic areas of focus for outsourced projects in the next 12 to 18 months

**8.5** DIFFERENT SERVICES

Oncology drug developers are looking to outsource an average of 8.5 different services in the next 12 to 18 months

## METHODS USED TO IDENTIFY OUTSOURCING PARTNERS



**3.1** AVERAGE # OF METHODS USED TO  
SELECT AN OUTSOURCING PARTNER



# OUTSOURCING ONCOLOGY PROJECTS TO EMERGING MARKETS

**75%** of respondents will consider CMOs in emerging markets for manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma


Respondents Who Outsource Oncology Projects and Consider CMOs in Emerging Markets by Buyer Group



**37%** of respondents are already working with CMOs in emerging markets on manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma

The Percentage by Buyer Group Who Are Already Working With CMOs in Emerging Markets on Oncology Projects



**14%** of respondents say the quality level is too risky to offshore manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma

The Percentage by Buyer Group Who Believe the Quality Level Is Too Risky to Offshore Oncology Projects




## MANUFACTURING SERVICES ENGAGED BY ONCOLOGY OUTSOURCERS




Development Services  
**26%**

■ Large Molecule API / Biologics  
■ Small Molecule API  
■ Injectables Product Development  
■ Solid Dose, Semi-Solids, & Liquid Development  
■ Other Delivery Forms (Inhalable / Transdermal)



Manufacturing Services  
**31%**

■ Large Molecule API / Biologics  
■ Small Molecule API & Advanced Intermediates  
■ Solid Dosage Forms  
■ Injectables  
■ Semi-Solids & Liquids  
■ Specialty Dosage Forms







JHP PHARMACEUTICALS NOW KNOWN  
AS PAR STERILE PRODUCTS, LLC

technology transfer... batch production... clinical trials... scale up... speed to market... FDA approval

## If you want to rest easy, it pays to partner with the right CMO.

The journey to commercial drug supply can be a real nightmare — unless you choose the right CMO partner. When you choose JHP Pharmaceuticals, you can count on a team of specialists who have spent years developing the systems, expertise and invaluable insight necessary to help you steer clear of potential problems that can keep you up at night. We've helped some of the biggest names in the drug and biotech world bring sterile injectable products to market quickly and efficiently.

From the first clinical supplies to final production of large commercial batches, our expert account team will be right by your side. In addition, our manufacturing facility is fully cGMP compliant and offers the ultimate flexibility should you need to scale up at a moment's notice to meet unexpected demand.

**JHP Pharmaceuticals. The decision you'll never lose sleep over.**

For details, call 1-877-906-7556 or visit [www.jhpharma.com](http://www.jhpharma.com)




PHASE I THROUGH COMMERCIAL    REGULATORY SUPPORT    LYOPHILIZATION    STERILE INJECTABLES    VACCINES    BIOLOGICS    OPHTHALMICS / OTICS

# MANUFACTURING SERVICES ENGAGED BY ONCOLOGY OUTSOURCERS


## DEVELOPMENT SERVICES BY BUYER GROUP

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma



## COMMERCIAL SCALE MANUFACTURING BY BUYER GROUP

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma





# Introducing a Commercial Facility for Today's Market

UPM Pharmaceutical's new 500,000 square foot commercial facility in Bristol, Tennessee serves customers with large-scale manufacturing capabilities for solid oral dosage tablets and capsules, as well as semi-solid creams and ointments.

## KEY SITE FEATURES:

- 500,000 square foot manufacturing facility
- 70,000 square feet of general warehouse storage
- 7,400 square feet of controlled substances storage
- Excellent regulatory inspection history (DEA-licensed)
- Comprehensive tech transfer support
- Pilot plant with scale-up capacity
- Analytical and microbial testing laboratories with dedicated suites for potent compounds

## LARGE-SCALE OPERATIONS:

- Blending
- Drying
- Compressing
- Semi-Solid Processing
- Milling / Sifting
- Granulating / Coating
- Encapsulating
- Packaging

## ANNUAL PRODUCTION CAPACITY:

- 3.5 billion tablets
- 700 million capsules
- 43 million packaged bottles
- 138,000 kilograms of cream / ointment
- 5 million packaged tubes / jars

To learn more, visit [www.upm-inc.com](http://www.upm-inc.com) or call +1 410 843 3738.



THE **CMO**  
LEADERSHIP  
AWARDS 2013

WINNER




INNOVATION PRODUCTIVITY REGULATORY





# OUTSOURCING PREFERENCES & PRACTICES ONCOLOGY PROJECTS

## OUTSOURCING RELATIONSHIPS

% of projects contracted to each type of outsourcing relationship



## INTEREST LEVEL IN A STRATEGIC PARTNERSHIP





*Any help with*  
**your manufacturing?**



**Rovi CM**

Contract Manufacturing Services

Above all, your partner

Tel.: +34 91 375 62 45 / Madrid SPAIN / [clopezdehierro@rovi.es](mailto:clopezdehierro@rovi.es) / [www.rovicm.es](http://www.rovicm.es)

# An Update On The Buzz Around Oncology

KATE HAMMEKE Contributing Editor

*The heightened interest in developing cancer treatments, combined with the R&D efforts put forth over the past decade, contributed to the emergence of a class of “smart bombs” first reported as one of their most hopeful developments at the American Society of Clinical Oncology’s annual meeting in June of 2012. These medicines use antibodies that bond to specific cancer cells to deliver a very toxic drug directly to the cancerous cell, leaving healthy tissue alone.*



In February of 2013, the FDA approved the first “smart bombs” to treat breast cancer, commercially known as Kadcyla and developed by Roche’s Genentech.

The second major development reported at the time was some degree of success in using the body’s own immune system to fight cancer, an idea that has been around for a century, but training the immune system to recognize the cancer cells as an “enemy” to attack had previously met with limited success. At present, there are still no FDA-approved drugs on the market that work using immunotherapy, but evidence from clinical trials testing PD-1 (a protein) blocking drugs have shown a “quantum leap” of progress. These potentially new kinds of therapies, combined with progress in diagnostic tests that help predict which medicines will work for which patients, are important tools in reducing cancer deaths and carry huge potential for the developers who bring them to market.

Eighteen oncology drugs were approved in 2012 (of 50 new drug approvals, including new molecular entities [NMEs] and biologic license applications

[BLAs]), 12 in 2013 (of 41) and one so far in 2014. This success rate has remained steady for the past few years, where oncology drugs comprise roughly one-third of the new drugs approved, with 36 percent in 2012 and 29 percent in 2013. The large number of medicines being developed for oncology is no surprise, as cancer is still a leading cause of death in the United States, second only to heart disease. The vast market for cancer medicines has secured its position as a therapeutic area of focus for the drug development pipelines of 38 percent of all pharmaceutical and biotechnology businesses — up five percentage points in the past three years.

In looking at the various sponsor segments, the data shows that 53 percent of Big Pharma companies have oncology drugs in their development pipeline, up from 45 percent in 2012. Biotech follows with 37 percent, a slight drop from 40 percent in 2012. Specialty pharma and emerging biotechs have ramped up oncology drug development, with a six-percentage-point increase over 2012, both rising from 29 percent to 35 percent. Emerging Pharma companies

had the smallest increase in developing oncology drugs, with a three-percentage-point increase from 18 to 21 percent.

## SIGNIFICANT EXPENDITURE AND HEAVY OUTSOURCING MEAN MARKET INFLUENCE

The results from the Nice Insight pharmaceutical and biotechnology outsourcing survey show that sponsors whose pipeline includes oncology medicines have broadened the base and are looking to outsource projects across an average of 3.5 different therapeutic areas of focus, up from 2.25 in 2012. These respondents were identified as heavy outsourcers in 2012, averaging 6.9 different services, as compared to the overall average of 5.3. This continues to be true and has shown solid gains, with an average of 8.5 different services outsourced as compared to the overall average of 6.4.

This heavy outsourcing is still accompanied by substantial outsourcing expenditure; however, spending is not quite as high as it was in 2012 when 41% of businesses whose therapeutic area of focus is oncology diseases indicated they would spend more than \$50M, as compared to 26 percent of the overall





# SIMPLIFY<sup>SM</sup>

## YOUR CONTRACT MANUFACTURING

Simplify your contract manufacturing with process development, cell-culture manufacturing, formulation development, vial and syringe filling and secondary packaging all in one location. Accelerate the delivery of your life-enhancing products to patients, and work with one point of contact and one set of business practices.

To see our capabilities videos, visit:  
[www.youtube.com/user/cookpharmica](http://www.youtube.com/user/cookpharmica)  
or contact our Business Development team  
at [busdev@cookpharmica.com](mailto:busdev@cookpharmica.com).




[www.cookpharmica.com](http://www.cookpharmica.com)

DEVELOPMENT • CLINICAL • COMMERCIAL • DRUG SUBSTANCE • DRUG PRODUCT

© COOK 2014 PH-BADV-LSCMO-EN-201406


## Oncology as a Therapeutic Area of Focus Among Each Buyer Group



## Outsourcing Drivers as Prioritized by Oncology Outsourcers



## The Percentage of Oncology Outsourcers That Engage Outsourcing Partners by Phase



**Survey Methodology:** The Nice Insight Pharmaceutical and Biotechnology Survey is deployed to outsourcing-facing pharmaceutical and biotechnology executives on an annual basis. The 2013-2014 report includes responses from 2,337 participants. The survey comprises more than 240 questions and randomly presents ~35 questions to each respondent in order to collect baseline information with respect to customer awareness and customer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of awareness, from "I've never heard of them" to "I've worked with them," factor into the overall customer awareness score. The customer perception score is based on six drivers in outsourcing: Quality, Innovation, Regulatory Track Record, Affordability, Productivity and Reliability. In addition to measuring customer awareness and perception information on specific companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partnerships among buyers of outsourced services.

respondent group. In 2013, this number decreased to 34 percent, as compared to 24 percent of the overall respondent group. In 2014, 45 percent indicated their expenditure would be between \$10M and \$50M, as compared to two years ago when 36 percent fell into this category. The percentage of respondents in the lowest-spending category remained the same — at 22 percent — from 2012 to 2014.


These traits — significant expenditure and heavy outsourcing — give the group considerable influence over the market size of the services they outsource. For this reason, among others, it pays to gain some traction in this therapeutic area. Four out of every five respondents prioritized a CMO's "Track record/History of success" with the highest level of importance when considering an outsourcing partner. Further, therapeutic experience adds appeal to a CMO's position as a strategic partner. **L**



➔ Kate is the director of marketing intelligence for Nice Insight, the research division of That's Nice. Kate runs all custom market research for the company, and she designed the first industrywide study on selecting outsourcing partners during the drug development cycle for the pharmaceutical and biotechnology sector. Kate continues to update the Nice Insight CRO/CMO research according to evolving industry trends, and she works on the development of Nice Insight's new subscription product on the excipients market. Kate has developed and coordinated custom research projects for more than 30 major brands in the Fortune 500. Using her industry knowledge, Kate has written dozens of articles related to pharmaceutical outsourcing for five industry magazines. She is a monthly contributor to *Life Science Leader* magazine, authoring the column "Outsourcing Insights."



# abbvie



## DRAW ON EXPERTISE

### ABBVIE CONTRACT MANUFACTURING

Biologics | Potent | Drug Product | APIs  
Prefilled Syringe | Hot Melt Extrusion | Fermentation

If you had the opportunity to draw your ideal CMO, we're confident your vision would look like AbbVie Contract Manufacturing. Partner with us, and you can benefit from experience and knowledge reflecting a century at the forefront of pharmaceutical development and manufacturing, and some of today's biggest drug success stories. We also bring a modern, agile approach, resulting in a relationship aligned with your vision, with commitment to your science.



Advance your project quickly and reliably.  
Contact AbbVie at +1 847 938 8524 or visit  
[www.abbviecontractmfg.com](http://www.abbviecontractmfg.com)

The prior Proprietary Pharmaceuticals business of Abbott Laboratories is now AbbVie.



THE **CMO**  
LEADERSHIP  
AWARDS 2013

WINNER



QUALITY INNOVATION PRODUCTIVITY REGULATORY

# BIOMANUFACTURING TRENDS IN 2014

The latest industry trends and proprietary data from Nice Insight survey results





# The Perfect Balance Between Timing, Quality and Value



## Accelerate your program from DNA to Commercialization

CMC Biologics will accelerate the development of your biopharmaceutical program from DNA through commercialization without sacrificing quality or increasing your project costs. We have learned through 13 years of experience that a faster development timeline can only be achieved with dedication to technical excellence, strong quality systems and our focus on exceptional customer satisfaction. From our facilities in Europe and the United States, we have successfully developed and manufactured over 80 biopharmaceutical products including monoclonal antibodies, coagulation factors and other proteins for customers across five continents. Strike the perfect balance for your project by choosing CMC Biologics as your development and manufacturing partner.

United States +1 425 485 1900 Europe +45 7020 9470 [www.cmcbiologics.com](http://www.cmcbiologics.com)



WINNER



QUALITY



RELIABILITY




INNOVATION

## RESPONDENT PROFILE INFORMATION

Research conducted by Nice Insight [n=643]


### BY COMPANY TYPE

■ Biotech ■ Emerging Biotech ■ Specialty Pharma ■ Big Pharma ■ Emerging Pharma






### BY ANNUAL OUTSOURCING EXPENDITURE

■ Less than 10M USD per year ■ 10 to 50M USD per year ■ 50M+ USD per year



### BY REGION



# 3.1

DIFFERENT THERAPEUTIC AREAS

Biomanufacturing outsourcers average 3.1 different therapeutic areas of focus for outsourced projects in the next 12 to 18 months

# 10.1

DIFFERENT SERVICES

Biomanufacturing outsourcers are looking to outsource an average of 10.1 different services in the next 12 to 18 months

### METHODS USED TO IDENTIFY OUTSOURCING PARTNERS




# 3.3

AVERAGE # OF METHODS USED TO SELECT AN OUTSOURCING PARTNER





*from Norwich Pharma Services*



CONTRACT

# DEVELOPMENT

CONTRACT

# CLINICAL RESEARCH

CONTRACT

# MANUFACTURING

FROM A SINGLE PROVIDER

Using Synchronized Outsourced Solutions from Norwich you can consolidate all of the services you need throughout your product's entire lifespan: from development and clinical research to commercialization and manufacturing. Norwich aligns each step of the process and seamlessly transitions your project throughout its lifecycle. And by consolidating services with a single provider, you'll have greater security, efficiency and consistency, which will get your product to market quicker and more cost-effectively.

Synchronize your next project » [norwichpharma.com](http://norwichpharma.com)



6826 State Highway 12, Norwich, NY 13815

# OUTSOURCING BIOMANUFACTURING TO EMERGING MARKETS

**85%** of respondents will consider CMOs in emerging markets for manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma

The Percentage by Buyer Group Who Would Consider Outsourcing to CMOs in Emerging Markets



**51%** of respondents are already working with CMOs in emerging markets on manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma

The Percentage by Buyer Group Who Are Already Working with CMOs in Emerging Markets on Biomanufacturing



**9%** of respondents say the quality level is too risky to offshore manufacturing projects

■ Biotech ■ Emerging Biotech ■ Big Pharma ■ Specialty Pharma ■ Emerging Pharma

The Percentage by Buyer Group Who Believe the Quality Level Is Too Risky to Offshore Biomanufacturing Projects





## BIOMANUFACTURING SERVICES OUTSOURCED



Mammalian Cell Culture  
**53%**

The Percentage of Respondents Who Outsource Mammalian Cell Culture Services to Emerging Market CMOs by Buyer Group



Microbial Manufacturing  
**65%**

The Percentage of Respondents Who Outsource Microbial Manufacturing Services to Emerging Market CMOs by Buyer Group



Vaccines  
**40%**

The Percentage of Respondents Who Outsource Vaccine production to Emerging Market CMOs by Buyer Group







## Passion for your Process, Product and Patients



### Development Services

Cell Line; Upstream;  
Downstream; Analytical



### cGMP Manufacturing

Upstream Production;  
Downstream Purification



### Aseptic Fill/Finish

Vials; Syringes;  
Lyophilization

Contract manufacturing of biologics is more than having superior technology – it's having experienced people who are passionate, responsive and committed to developing and manufacturing your biotherapeutics to improve patient care.

**We invite you to feel the difference at Therapure Biomanufacturing, where the client experience is our passion and patient care is our commitment.**

Please visit us at

[www.therapurebio.com/CDMO](http://www.therapurebio.com/CDMO)

Or contact:

**Dina Iezzi**

Director, Marketing & Special Projects

Phone: +1 (905) 286-6270

Mobile: +1 (647) 234-3395


Email: [diezzi@therapurebio.com](mailto:diezzi@therapurebio.com)

# OUTSOURCING PREFERENCES & PRACTICES



## BIOMANUFACTURING PROJECTS

### OUTSOURCING RELATIONSHIPS

% of projects contracted to each type of outsourcing relationship



### INTEREST LEVEL IN A STRATEGIC PARTNERSHIP



# THE POWER OF COMPLEMENTARY CAPABILITIES

GLOBAL REACH | SECURITY OF SUPPLY | EFFICIENCY



Let's talk

KNOWLEDGE | EXPERIENCE | EXPERTISE

Call +1-224-212-2267 or +44 (0) 1926 835 554  
or e-mail [one2one@hospira.com](mailto:one2one@hospira.com)



PARENTERAL CONTRACT MANUFACTURING  
SERVICE OF HOSPIRA



Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045  
P14-0264-3-8.25x10.875-Apr., 14

PLEASE VISIT US AT

Contract Pharma 2014

# Outsourcing Biomanufacturing Continues To Grow In Frequency

KATE HAMMEKE Contributing Editor

*Nice Insight has learned from its strategic partnering surveys that the long-term strategies of many businesses in the pharmaceutical industry for maintaining a strong drug development pipeline include integration of biopharmaceuticals.*



This integration can take several different forms, from partnerships with large biopharmas (56 percent), purchase of a small biopharma company (51 percent), partnering with a small biopharma (37 percent), or simply purchasing a biopharma's compounds (22 percent). These activities are motivated by the demonstrated profitability of biopharmaceuticals. The practice of partnering with or acquiring biopharmaceutical companies is mirrored in the results of Nice Insight's annual survey, where the percentage of respondents whose businesses are engaged in the development of biologic-based therapeutics continues to increase — up two percentage points from 71 percent in 2012 to 73 percent in 2014.

Spend on biologics development now consumes a slightly larger portion of these businesses' annual expenditure as well: 57 percent in 2014 as compared to 54 percent in 2012. Such expenditure continues to show promise for contract service providers both in winning outsourced biomanufacturing projects and in manufacturing biosimilars/bioequivalents for the biologics that come off pat-

ent in the coming decade. Now is a good time to start considering CMOs for these projects.

## OVERALL EXCELLENCE IN CUSTOMER PERCEPTION PLAYS A STRONG ROLE IN CMO SELECTION

Interest in identifying quality suppliers for biomanufacturing services prompted the expansion of Nice Insight's research to include specific questions about buyers' habits when outsourcing mammalian and microbial manufacturing, as well as their supplier preferences. According to the 2014 study, 53 percent of respondents who will outsource biomanufacturing would engage a CMO for mammalian cell culture. In reviewing the companies that were most likely to be considered for this type of project, it was clear that overall excellence in customer perception played a strong role. In fact, these companies averaged excellent ratings (between 80 and 100 percent) from respondents who outsource mammalian cell culture in four out of five categories. Quality was the single category where scores fell slightly below the excellent range (by 2 percentage points).

The top companies considered for mammalian cell culture projects were GSK Contract Manufacturing, Boehringer Ingelheim, CMC Biologics, Lonza, and KBI Biopharma.

Microbial manufacturing was reported to be outsourced with greater frequency than mammalian cell culture, with nearly two-thirds of respondents who will outsource biomanufacturing reporting they would outsource microbial manufacturing (65 percent). Three of the companies that were most likely to be considered for mammalian cell culture also made the top five for microbial manufacturing: GSK Contract Manufacturing, Boehringer Ingelheim, and Lonza. Pfizer CentreSource and Althea rounded out the top five companies most likely to be considered for a microbial manufacturing project. While the highest scores among the top five companies were in reliability and regulatory, these companies averaged excellent scores in all five categories.

Nice Insight also reviewed the scores from a broader group of CMOs for both mammalian cell culture and microbial manufacturing to see where these companies received their highest scores.





## Uniquely Flexible CMO™

Rose, Quality Assurance Scientist

### Flexibility Across All Phases

Gallus is a pure-play contract manufacturer of protein therapeutics offering significant strategic appeal.

- ▶ Extensive Process Development Capabilities
- ▶ Expertise in Fed-Batch & Perfusion
- ▶ Choice of Single-Use & Stainless Technologies
- ▶ Clinical & Commercial cGMP Suites
- ▶ Long-term Exemplary Regulatory Record
- ▶ Twenty-five Year Track Record in Aseptic Liquid Filling
- ▶ Collaborative & Transparent Client-Focused Approach

Contact Gallus to learn how far we will go to work for you.  
[info@gallusbiopharma.com](mailto:info@gallusbiopharma.com) | [www.gallusbiopharma.com](http://www.gallusbiopharma.com)

**gallus**

THE **CMO**  
LEADERSHIP  
AWARDS 2013

WINNER



REGULATORY PRODUCTIVITY



© Copyright 2014 Gallus BioPharmaceuticals, LLC. All rights reserved.

## Among Respondents Who Will Outsource Biomanufacturing

Mammalian  
Cell Culture


53%

Microbial  
Manufacturing


65%

Top Five Companies Considered for  
Mammalian Cell Culture Projects


## PERCENTILE RANK




## AVERAGE SCORE AMONG TOP 5

Top Five Companies Considered for  
Microbial Manufacturing Projects

## PERCENTILE RANK



## AVERAGE SCORE AMONG TOP 5



The data showed that among microbial manufacturing CMOs, the companies received their best scores in Reliability and Regulatory. For mammalian cell culture CMOs, the best scores across the group were in Reliability and Innovation. It will be interesting to see from future research if CMOs increase the chances of being considered for a project if they improve on these outsourcing measures.

The percentage of new drugs to market that are biologic based continues to rise — from 26 percent of new approvals in 2011 to 29 percent in 2013 — which means it's a good time to identify prospective outsourcing partners and begin to develop relationships. Consideration of the companies mentioned above is a good start, but doing so may end up costing more than joining forces with a smaller, lesser-known CMO. In which case, outsourcers of microbial manufacturing can start by looking for contract manufacturers with strong Reliability and Regulatory scores. Those looking to engage a CMO for mammalian cell culture should look for companies with strong Reliability and Innovation scores, or select one of the most frequently considered companies that showed excellence across four categories. [L](#)

**Survey Methodology:** The Nice Insight Pharmaceutical and Biotechnology Survey is deployed to outsourcing-facing pharmaceutical and biotechnology executives on an annual basis. The 2013-2014 report includes responses from 2,337 participants. The survey is comprised of 240+ questions and randomly presents ~35 questions to each respondent in order to collect baseline information with respect to customer awareness and customer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of awareness from "I've never heard of them" to "I've worked with them" factor into the overall customer awareness score. The customer perception score is based on six drivers in outsourcing: Quality, Innovation, Regulatory, Affordability, Productivity and Reliability. In addition to measuring customer awareness and perception information on specific companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partnerships among buyers of outsourced services.

# Unlock Worlds of Potential With Our End-to-End High Containment Expertise.



Guiding your high potency, solid oral dose drug project successfully from early development to commercial scale requires world-class assets and advanced expertise. Pfizer CentreSource applies a complete end-to-end suite of industry-leading high-containment services to move your project seamlessly from stage to stage and get you to market faster.

Our facilities in Germany, Ireland and Italy are equipped with the world's most advanced processing assets, technology and expertise. Included are award-winning engineered containment platforms as well as segregation-based models, each with the flexibility to support your specific needs and take promising new molecules from early development, scale-up, and clinical supply to

commercial production. Our robust high-potency services include sieving, milling and blending; high shear wet granulation and dry granulation; core compression, encapsulation and aqueous film coating; and complex packaging capabilities. We also apply industry-leading development, analytical, and regulatory expertise to accelerate your project and amplify your success.

High containment services from Pfizer CentreSource reflect Pfizer's uncompromised commitment to quality and compliance with global standards, coupled with our dedication to 100% customer satisfaction. So don't trust your molecule to anything less than the world's leading high-containment processing resource. Call or visit us online to start the conversation.

---

The Americas: +1.269.833.5844 Europe/Middle East/Africa: +32.2.714.6502 Asia Pacific: +65.6419.0248  
[centresource.info@pfizer.com](mailto:centresource.info@pfizer.com) [www.pfizercentresource.com](http://www.pfizercentresource.com)



# 2014 TRENDS AMONG EMERGING / NICHE & START-UP BUYERS

The latest industry trends and proprietary data from Nice Insight survey results



Research from Nice Insight's pharmaceutical and biotechnology outsourcing survey has shown that buyers of outsourced services have differing viewpoints when it comes to strategic partnerships. The research explores how phase of development or the services outsourced factor into a buyer's desire to form a strategic partnership. The data has also shown that company type, such as Big Pharma vs Biotech, and company size play an important role in identifying the right CMO for a project or partnership.



# TRAINING THAT'S **ANYWHERE** YOU ARE

**Training.** You need it and regulators require it. Travel costs, busy schedules, and different requirements make selecting and attending courses difficult. The Life Science Training Institute (LSTI) has your solution for the most up-to-date training for pharmaceutical, biotech, and medical device professionals.



**Actionable content that blends the detail of the classroom with the affordability and convenience of online training**

**Courses customized and delivered online or at your facility**

**Adult learning: Subject Matter Experts who understand *how* to teach, not just *what* to teach**

For more information about upcoming courses,  
contact [info@lifesciencetraininginstitute.com](mailto:info@lifesciencetraininginstitute.com) or 215-675-1800

**Actionable, Practical Instruction  
For Life Science Professionals**

 **LIFE SCIENCE**  
TRAINING INSTITUTE  
[www.lifesciencetraininginstitute.com](http://www.lifesciencetraininginstitute.com)



101 Gibraltar Road, Suite 100 | Horsham, PA 19044 | PH: (215) 675-1800

# RESPONDENT PROFILE INFORMATION

Research conducted by Nice Insight [n=713]

## BY COMPANY TYPE


Emerging Pharma Emerging Biotech






## BY ANNUAL OUTSOURCING EXPENDITURE

Emerging Pharma Emerging Biotech

Less than 10M USD per year 10 to 50M USD per year 50M+ USD per year



## BY REGION



Average # of different therapeutic areas of focus for outsourced projects in the next 12 to 18 months

**1.8** **2.7**

Emerging Pharma

Emerging Biotech

Average # of different services companies will outsource in the next 12 to 18 months

**5.5** **7.6**

Emerging Pharma

Emerging Biotech

## METHODS USED TO IDENTIFY OUTSOURCING PARTNERS



**3.4** AVERAGE # OF METHODS USED TO SELECT AN OUTSOURCING PARTNER

Emerging Pharma Emerging Biotech

Industry Research

Consultants

Referrals & Colleagues

Trade Shows & Events

Periodicals & Publications

Online Directories

Web Searches



55% 62%



56% 51%



60% 58%



39% 53%



26% 47%



21% 41%





26% 24%



# Moving Science

Moving Science To Commercialization



  
**Ash Stevens®**  
Small Molecule API Manufacturing

Call our team +1 734 282 3370

[www.ashstevens.com](http://www.ashstevens.com)

## Benefit From 50 Years Of CMO Knowledge

Ash Stevens has over five decades of experience developing and manufacturing drug substance. From our earliest origins to our present day state-of-the-art cGMP manufacturing facility in Riverview, Michigan, Ash Stevens has remained committed to moving projects forward to commercialization through high quality science, regulatory excellence, safe operations, integrity, and customer satisfaction. We serve clients of all sizes, from virtual biotech to large pharma, and from grams to metric tons.

# MANUFACTURING SERVICES ENGAGED BY EMERGING/ NICHE & START-UP BUYERS



Development &  
Phase I/II Clinical Trial  
Material Services

17%


Emerging Pharma

24%

Emerging Biotech

Development Services by Buyer Group

Emerging Pharma Emerging Biotech



Commercial Scale  
Manufacturing  
Services

22%

Emerging Pharma

25%

Emerging Biotech

Manufacturing Services by Buyer Group


Emerging Pharma Emerging Biotech



## OUTSOURCING TO EMERGING MARKETS AMONG EMERGING/ NICHE AND START-UP BUYERS


Emerging/Niche & Start-up Buyers Who Would Consider CMOs in Emerging Markets

Emerging Pharma Emerging Biotech



The Percentage Who Are Already Working With CMOs in Emerging Markets

Emerging Pharma Emerging Biotech



The Percentage Who Believe the Quality Level Is Too Risky

Emerging Pharma Emerging Biotech






See what we're made of.



## Our Services Include:

- Formulation Development
- Clinical-Commercial Manufacturing
- Method Development
- Analytical Testing
- Stability Program Management

Find out more about our  
Stability Services online  
at [corerxpharma.com](http://corerxpharma.com)




Visit us at [corerxpharma.com](http://corerxpharma.com)

Follow us on Twitter - [twitter.com/CoreRx](https://twitter.com/CoreRx)

# OUTSOURCING PREFERENCES & PRACTICES AMONG EMERGING/ NICHE AND START-UP BUYERS


## OUTSOURCING RELATIONSHIPS

% of projects contracted to each type of outsourcing relationship



## INTEREST LEVEL IN A STRATEGIC PARTNERSHIP

Emerging Pharma Emerging Biotech





# The ART of SMARTSOURCING™

Mastering your drug discovery through to early development requires access to detailed problem-solving, intellectual project management and sophisticated tool sets.

Our locations in North America and Asia are bolstered by years of deep Pharma discovery expertise. Technically, we've stood where you stand and know how to shine a light on the valuable stepping stones that exist on the pathway from target drug discovery through pre-clinical development.

Inventively progress the success of your compound with AMRI SMARTSOURCING™.

**Headquarters:** Albany Molecular Research, Inc.  
26 Corporate Circle, Albany, NY 12203 USA  
**Contact:** 518.512.2345 | James.Grabowski@amriglobal.com  
**Website:** www.amriglobal.com



**AMRI®**  
Albany Molecular Research Inc.

Discovery and Development

API Manufacturing

Drug Product Manufacturing



# Following The Lead From Big Pharma Or Biotech May Not Identify The Right Supplier For Emerging/Niche Or Start-Up Companies

KATE HAMMEKE Contributing Editor

*A couple of years ago, Nice Insight explored how the essential qualities for outsourcing relationships varied between large and midsize companies, in addition to traditional pharma companies versus biotechs. As one would imagine, these essentials differ quite a bit from emerging or start-up companies, as their needs when it comes to outsourcing are different from larger companies'.*



**O**ftentimes the company is too new to the industry to have a well-established process for selecting providers or a track record of what has worked well in the past. To further complicate matters, it is not uncommon for senior leadership at start-up companies to have a history at a Big Pharma or biotech and to be brought on for their expertise — which is a strong positive in many aspects of running a successful business but not necessarily in finding the right type of outsourcing partner.

Folks in the biopharmaceutical industry know that identifying which qualities make the greatest contribution to a positive relationship with an outsourcing partner is an ongoing and ever-changing process. The fluid nature of the drug development industry — one that is constantly adapting to new health challenges, technologies, and regulations — is part of what makes it so difficult to outline which attributes in a contract manufacturer should be prioritized so that the relationship functions like a strategic partnership in which both the buyer and CMO benefit. The continual transforma-

tion of drug development reiterates the importance of keeping an open mind and learning from the successes of one's industry peers. That way, the pressure to find the right business for a project diminishes and is replaced by confidence in finding a company with the right mix of attributes that will make for a successful long-term partnership.

## PRACTICES OF EMERGING PHARMA AND EMERGING BIOTECH COMPANIES DIFFER

Nice Insight reviewed the outsourcing behaviors and strategic partnering preferences of respondents who work at emerging / niche or start-up pharmaceutical companies and those who work at emerging or virtual biotechs to see how these smaller businesses identify CMOs and develop mutually beneficial relationships. Starting with the methods used to identify potential outsourcing partners, Nice Insight found that the practices of emerging pharma companies and emerging biotechs differ. Emerging pharma relies on referrals from colleagues as their main resource (60 percent), whereas emerging biotechs use industry research to identify potential CMOs (62 percent).

Emerging pharma companies are more likely to seek advice from consultants on outsourcing (56 percent as compared to 51 percent of emerging biotechs), while emerging biotechs are more likely to seek out suppliers at trade shows than emerging pharma companies (53 percent vs. 39 percent).

The primary reason for engaging contract manufacturers — improving quality — was consistent between emerging pharma, Big Pharma, and Biotech companies; however, among emerging biotech respondents, this trait came in second after improving time to market. It is no surprise that cost savings are a key factor in outsourcing. Whether it is decreasing fixed costs or capital investment, reducing financial outlay proved important among established and emerging companies and for both traditional pharma and biotechs.

An interesting area where outsourcing motivations diverged between emerging companies is the desire to gain operational expertise: prioritized fourth among emerging pharma companies but ranked eighth among emerging biotech companies. Mitigating supply




## Compare impartial peer reviews to find your ideal CRO



*Company No. 1*

*Company looking to extend  
a compound's stability*

*Formulation variables  
impact supply to patients*



*Company No. 2*

*Demand increases for highly  
potent compound*

*Elevation in operator  
experience required*



*Company No. 3*

*Hazardous chemistry  
market grows*


*Few CMOs have these  
capabilities*



*Company No. 4*

*Lyophilization option  
offered over liquid fill*

*Shelf life stability technology  
brings value to CMO*



*Company No. 5*

*Mammalian cell line selected  
over microbial cell line*

*cGMP procedures  
very different*

Sample Nice Insight with open access to limited top line data on our website – optimized for smart phones, tablets and desktops

Nice Insight is unique in enabling you to compare a large number of CROs based on impartial reviews from thousands of respected peers that buy outsourced services, rather than relying on the typical claims that make them all appear the same. Learn who is rated highest for the leading drivers: quality, reliability, regulatory, affordability, productivity and innovation – and quickly establish a shortlist that best aligns with your strategy.

**Search. Compare. Contact.**

For more information, contact Nigel Walker, Managing Director at [nigel@thatsnice.com](mailto:nigel@thatsnice.com) or +1 212 366 4455.

[www.niceinsight.com](http://www.niceinsight.com)


**niceinsight**

Marketing Intelligence by That's Nice

## Attributes that Factor into CMO Selection



## Prioritized Strategic Partner Attributes by Buyer Category



## Motivations for Engaging a CMO



**Survey Methodology:** The Nice Insight Pharmaceutical and Biotechnology Survey is deployed to outsourcing-facing pharmaceutical and biotechnology executives on an annual basis. The 2013-2014 report includes responses from 2,337 participants. The survey is comprised of 240+ questions and randomly presents ~35 questions to each respondent in order to collect baseline information with respect to customer awareness and customer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of awareness from "I've never heard of them" to "I've worked with them" factor into the overall customer awareness score. The customer perception score is based on six drivers in outsourcing: Quality, Innovation, Regulatory Track Record, Affordability, Productivity, and Reliability. In addition to measuring customer awareness and perception information on specific companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partnerships among buyers of outsourced services.

chain risk carried greater importance among emerging pharma companies than among emerging biotechs (5th position vs. 10th). Conversely, emerging biotech companies ranked general process improvement much higher than emerging pharma (6th position vs. 10th).

When it comes to selecting a CMO, the number one factor for both emerging pharma companies and emerging biotechs is experience. Experience is one of two common rankings between these two buyer groups, the other being "risk sharing opportunities" in fifth position. Emerging pharma placed the CMO's financial stability over quality and timeliness (3rd and 4th, respectively), whereas emerging biotechs ranked financial stability after those merits, identifying quality/regulatory positioning as their second priority, followed by timeliness. Neither emerging pharmas nor emerging biotechs placed much importance on the size and structure of the CMO or its geographical location.

As a contract manufacturer, you should apply this knowledge to pitch the right company strengths to the relevant audience in key sales communications, which will more strategically position your business. Emerging companies that understand how other buyers identify and prioritize CMO qualities before engaging a provider can eliminate some of the trial and error elements of vendor selection and serve as an advantage with respect to strategic decision making in outsourcing. **L**




N. WALKER



S. FAZZOLARI

➔ If you want to learn more about the report or about how to participate, please contact Nigel Walker, managing director, or Salvatore Fazzolari, director of client services, at Nice Insight by sending an email to [niceinsight.survey@thatsnice.com](mailto:niceinsight.survey@thatsnice.com).

# Committed to Global Innovation For Human Health



## Your Strategic Partner for Successful Therapeutic Design, Development and Production

As a committed partner to the pharmaceutical and biotechnology industry, Lonza recognizes the need for established and dependable global manufacturing facilities. Together with our process innovation, proprietary technologies, project management, regulatory expertise, and global footprint, we are well positioned to meet your outsourcing needs at any scale. We offer a full range of services from preclinical risk assessment of your candidates to full-scale commercial manufacturing.

View a virtual tour of our state-of-the-art manufacturing sites at  
[www.lonzavirtualtours.com](http://www.lonzavirtualtours.com)

### Custom Services Include:

- Risk Assessment
- Cell and Viral Therapies
- Mammalian Biopharmaceuticals
- Microbial Biopharmaceuticals
- Antibody Drug Conjugates
- Cytotoxics
- Highly Potent APIs
- Peptides
- Small Molecules
- Vaccines

# Introducing

## **SoluPath** *Flex*<sup>TM</sup>

*A new low solubility solution*



### The Customizable, Fixed-Price Solution to Rapidly Improve Solubility

Never before has it been so fast and simple to overcome solubility challenges. With SoluPath *Flex*<sup>TM</sup>, you'll have access to the choices and scientific expertise you need to meet your unique needs.

- Full array of solubility technologies and services.
- Hand-pick the services for your molecule and business.
- Know all costs, timelines and API requirements in advance.

- Consult with a solubility expert at the earliest stages.
- Plan, quote and launch project in days.
- Rapid results from dedicated equipment and teams.

Only with SoluPath *Flex*<sup>TM</sup> can you accelerate development with a solubility enhancement solution custom tailored to meet the specific requirements of your molecule, timeline and budget. Plus, you can finalize your plan with a solubility expert in just one meeting.

Get exactly what you need, and get it faster with SoluPath *Flex*<sup>TM</sup>

Visit our booth #403 at the CRS Annual Meeting

+1 866.PATHEON • [www.pattheon.com](http://www.pattheon.com) • [doingbusiness@pattheon.com](mailto:doingbusiness@pattheon.com)

©Pattheon Inc. All rights reserved. Published 4/14 PATH0364R2

**Pattheon**<sup>®</sup>  
Performance the World Over<sup>®</sup>